These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 25341887)

  • 1. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
    Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA
    J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease.
    Hodges G; Lyngbæk S; Selmer C; Ahlehoff O; Theilade S; Sehestedt TB; Abildgaard U; Eugen-Olsen J; Galløe AM; Hansen PR; Jeppesen JL; Bang CN
    Scand Cardiovasc J; 2020 Dec; 54(6):339-345. PubMed ID: 32400206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathway-Specific Aggregate Biomarker Risk Score Is Associated With Burden of Coronary Artery Disease and Predicts Near-Term Risk of Myocardial Infarction and Death.
    Ghasemzedah N; Hayek SS; Ko YA; Eapen DJ; Patel RS; Manocha P; Al Kassem H; Khayata M; Veledar E; Kremastinos D; Thorball CW; Pielak T; Sikora S; Zafari AM; Lerakis S; Sperling L; Vaccarino V; Epstein SE; Quyyumi AA
    Circ Cardiovasc Qual Outcomes; 2017 Mar; 10(3):. PubMed ID: 28280039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
    Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
    J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
    Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
    Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
    Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
    J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease.
    Al-Badri A; Tahhan AS; Sabbak N; Alkhoder A; Liu C; Ko YA; Vaccarino V; Martini A; Sidoti A; Goodwin C; Ghazzal B; Beshiri A; Murtagh G; Mehta PK; Quyyumi AA
    J Am Heart Assoc; 2020 Apr; 9(8):e015515. PubMed ID: 32301366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
    Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
    Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
    Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
    Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease.
    Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA
    J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
    Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
    Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
    Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
    JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
    Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
    Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
    [No Abstract]   [Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study.
    Walter JE; Amrein MLF; Schäfer I; Zimmermann T; Lopez-Ayala P; Boeddinghaus J; Twerenbold R; Puelacher C; Nestelberger T; Wussler D; Honegger U; Badertscher P; Eugen-Olsen J; Koechlin L; Fahrni G; Jeger R; Kaiser C; Zellweger M; Mueller C
    Biomarkers; 2022 May; 27(3):278-285. PubMed ID: 35112976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
    Persson M; Östling G; Smith G; Hamrefors V; Melander O; Hedblad B; Engström G
    Stroke; 2014 Jan; 45(1):18-23. PubMed ID: 24253546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina.
    Zebrack JS; Muhlestein JB; Horne BD; Anderson JL;
    J Am Coll Cardiol; 2002 Feb; 39(4):632-7. PubMed ID: 11849862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.
    Topel ML; Sandesara PB; Stahl EP; Hayek SS; Tahhan AS; O'Neal WT; Ko YA; Alkhoder A; Gafeer MM; Kim JH; Wilson PWF; Shaw LJ; Epstein SE; Vaccarino V; Sperling LS; Quyyumi AA
    Int J Cardiol; 2019 Feb; 276():255-260. PubMed ID: 30217423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Molecule Counting of High-Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) Study.
    McCarthy CP; Ibrahim NE; Lyass A; Li Y; Gaggin HK; Simon ML; Mukai R; Gandhi P; Kelly N; Motiwala SR; van Kimmenade RRJ; Massaro JM; D'Agostino RB; Januzzi JL
    J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29519811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.